Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
In Vivo. 2024 Mar-Apr;38(2):890-896. doi: 10.21873/invivo.13515.
BACKGROUND/AIM: This study aimed to evaluate the clinical impact of the Naples Prognostic Score (NPS) in patients with gastric cancer and to clarify the potential of the NPS as a nutritional and inflammation evaluation system.
This study included 158 patients who underwent curative treatment for gastric cancer between 2005 and 2020. The prognosis and clinical pathological parameters of the high-NPS (NPS >2) and low-NPS (NPS=0, 1) groups were analyzed.
The overall survival (OS) rates at 3 and 5 years were 86.7% and 77.7%, respectively, in the low-NPS group and 55.4% and 47.4%, respectively, in the high-NPS group. There were significant differences in OS between the two groups. Uni- and multivariate analyses demonstrated that the NPS was an independent prognostic factor for OS (HR=2.495, 95%CI=1.240-5.451). In addition, the 3- and 5-year recurrence-free survival (RFS) rates were 82.1% and 76.0%, respectively, in the NPS-low group, and 43.8% and 36.6% in the NPS-high group. Univariate and multivariate analyses demonstrated that the NPS was an independent prognostic factor for RFS (HR=2.739, 95%CI=1.509-4.972). When the first site of recurrence was compared between the low-NPS group and high-NPS group, there were significant differences in peritoneal recurrence (8.7% vs. 34.3%, p=0.001) and hematologic recurrence (5.6% vs. 21.9%, p=0.004).
The NPS was a significant prognostic factor in patients with gastric cancer who received curative treatment. The NPS may be a promising biomarker for the treatment and management of gastric cancer.
背景/目的：本研究旨在评估那不勒斯预后评分（NPS）在胃癌患者中的临床影响，并阐明 NPS 作为一种营养和炎症评估系统的潜力。
本研究纳入了 158 例 2005 年至 2020 年间接受胃癌根治性治疗的患者。分析了高 NPS（NPS>2）和低 NPS（NPS=0，1）组的预后和临床病理参数。
低 NPS 组的总生存期（OS）在 3 年和 5 年时分别为 86.7%和 77.7%，高 NPS 组分别为 55.4%和 47.4%。两组之间的 OS 存在显著差异。单因素和多因素分析表明，NPS 是 OS 的独立预后因素（HR=2.495，95%CI=1.240-5.451）。此外，NPS 低组的 3 年和 5 年无复发生存率（RFS）分别为 82.1%和 76.0%，NPS 高组分别为 43.8%和 36.6%。单因素和多因素分析表明，NPS 是 RFS 的独立预后因素（HR=2.739，95%CI=1.509-4.972）。在低 NPS 组和高 NPS 组之间比较首次复发部位时，腹膜复发（8.7% vs. 34.3%，p=0.001）和血液学复发（5.6% vs. 21.9%，p=0.004）存在显著差异。
NPS 是接受根治性治疗的胃癌患者的显著预后因素。NPS 可能是治疗和管理胃癌的有前途的生物标志物。
